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Abstract 
A blood pressure (BP) category defined with both systolic (SBP) and diastolic blood pressure 
(DBP) is commonly used. However, BP category-specific cardiovascular disease (CVD) risk 
has not been thoroughly investigated in aged populations. The aim of this study is to assess 
long-term CVD risk and its impact according to BP categories by age groups. 
Pooling individual data from 10 cohorts, we studied 67,309 Japanese men and women (40 to 
89 years) free of CVD at baseline according to three age groups: “middle-aged” (40-64 years), 
“elderly” (65-74 years), and “very elderly” (75-89 years). BP was classified according to the 
2009 Japanese Society of Hypertension guidelines. Cox models were used to estimate 
multivariable adjusted hazard ratios for CVD death.  
We observed 1,944 CVD deaths over a mean follow-up of 10.2 years. In all age groups, the 
overall relationship of BP categories with CVD risk was positive and graded with greater 
strength seen with younger age. We observed a trend of increase in risk from SBP/DBP 
≥130/85 mmHg in the very elderly, and a significant increase from SBP/DBP ≥120/80 mmHg 
in the other age groups. The population attributable fractions (PAFs) of CVD death beyond 
the SBP/DBP <120/80 mmHg category ranged from 23.4% in the very elderly to 60.3% in the 
middle-aged. 
We found an overall graded increase in CVD risk according to BP category in the very elderly. 
The corresponding PAF suggest that keeping BP levels low is an important strategy for 
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primary CVD prevention even in an elderly population. 
 
Key Words: blood pressure category, cardiovascular death, cohort, elderly, population 
attributable fraction 
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INTRODUCTION 
Epidemiological studies have shown that the effect of both systolic blood pressure (SBP) and 
diastolic blood pressure (DBP) on the risk for cardiovascular disease (CVD) is continuous and 
consistent 1, 2.  Because both SBP and DBP are independent predictors of CVD risk 3-7, 
current guidelines on adult blood pressure (BP) management have agreed on the following: 
(1) BP category is defined by taking both SBP and DBP into account, and (2) the most 
favorable BP category is SBP <120 mmHg and DBP <80 mmHg, irrespective of age 8-11. 
 
Although such BP categorization is widely used, only limited evidence is available that 
assesses long-term cardiovascular disease (CVD) risk according to BP categories, particularly 
among an elderly population. Given the worldwide trend of an aging 12, assessing long-term 
risk of elevated BP and its impact on aged population is increasingly important from both 
clinical and public health standpoints. The Framingham Heart Study reported graded 
increases in major CVD risk across higher BP categories among 1932 participants aged 80 
years or older 13. However, their follow-up period was relatively short (mean, 2.7 years) 13. 
Therefore, long-term CVD risk was not fully demonstrated in that study. Other Western 
studies seeking BP-category specific risk on CVD events were based on subjects aged 75 
years or younger 5, 14-16. Epidemiological studies on long-term CVD risk among an elderly 
population are also limited 17, 18, hence needed19, in Asia. 
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The objectives of this study are to (1) estimate long-term CVD mortality risk according to BP 
categories defined by both SBP and DBP; (2) examine whether the relationship of BP 
category and CVD risk differs by age groups; and (3) compare the impact of increased BP on 
long-term CVD risk among different age groups by population attributable fractions (PAFs). 
We particularly focused on an elderly population. 
 
METHODS 
Design 
This study is a part of a pooling project in which individual participants’ data from 13 
observational cohorts across Japan were combined. The project was designed to examine the 
relationship between disease mortality and various exposure factors including laboratory and 
lifestyle/behavioral factors. The project is called Evidence for Cardiovascular Prevention from 
Observational Cohorts in Japan (EPOCH-JAPAN). The inclusion criteria for a cohort were as 
follows: collection of health examination measures, follow-up of almost 10 years, and a 
number of participants greater than 1,000. Both nationwide and regional cohort studies were 
included. Other details were reported elsewhere 20. 
 
Study population 
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Ten of 13 cohorts provided data on cause of death (n=90,528). Of those, we used the 
following exclusion criteria for the present study: age younger than 40 years or older than 89 
years at baseline (n=10,528); history of cardiovascular disease at baseline (n=5,031); missing 
values for SBP, DBP, or both (n=147); and missing adjusting covariates (n=7,513). Thus, 
67,309 individuals from 10 cohort studies were pooled (Tanno-Sobetsu, Ohsaki, Ohasama, 
Oyabe, YKK workers, the Radiation Effects Research Foundation (RFRF) cohort, Hsayama, 
JACC study, NIPPON DATA80, and NIPPON DATA90; see supplemental TableS1 for 
demographics of each cohort). 
 
Death ascertainment 
In accordance with the Family Registration Law in Japan, all death certificates are forwarded 
to the Ministry of Health, Labour, and Welfare via the public health center in the area of 
residency. Registration of death is required by Law and believed to be complete. The 
underlying cause of death is coded according to the International Classification of Disease 
(ICD) for the National Vital Statistics based on the criteria proposed by World Health 
Organization 21. 
 
Cause of death was sought in great detail using the available sources in each cohort study. In 
most studies, death certificates were reviewed and/or the National Vital Statistics were used 
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after obtaining permission. Other sources used in some studies included autopsy, medical 
records, health examination, and questionnaires. Cause of death was coded based on either 
ICD-9 or ICD-10. Classification codes used in the study were as follows: death from CVD 
(390-459 by ICD9; I00-I99 by ICD10), total stroke (410-414 or 430-438; I20-I25 or I60-I69), 
ischemic stroke (433 or 434 or 437.8; I63 or I69.3), intracerebral hemorrhage (431-432; I61 
or I69.1), coronary heart disease (CHD) (410-414; I20-I25), and heart failure (428; I50). 
 
BP measurement 
The detailed information for BP measurement method in each cohort was provided in 
supplemental table S2.  BP measurements were obtained using a mercury 
sphygmomanometer from a participant in a seated position in all but two cohort studies. In 
one cohort (Ohasama), an automated device was used22. In the other study (JACC), BP values 
were based on self-recorded values after BP was measured at a health check-up23. In most 
cohorts, BP was measured once with a participant in seated position after a rest.  
 
BP categories 
Participants were categorized according to the modified classification of 2009 Japanese 
Society of Hypertension guidelines (JSH2009) 10. The cut-off values for the BP classification 
were same as the 2007 Guidelines by the European Society of Hypertension and of the 
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European Society of Cardiology (ESH-ESC 2007) 8. Optimal BP was defined as SBP <120 
mm Hg and DBP <80 mm Hg; the corresponding SBP and DBP values were 120–129 mm Hg 
and 80–84 mm Hg for normal/non-optimal BP, 130–139 mm Hg or 85–89 mm Hg (whichever 
was greater) for high-normal BP, 140–159 mm Hg or 90–99 mm Hg for Grade I hypertension, 
160–179 mm Hg or 100–109 mm Hg for Grade II hypertension, and ≥180 mm Hg or ≥110 
mm Hg for Grade III hypertension. 
 
Statistical Analysis 
We estimated multivariable adjusted hazard ratios (HRs) of death from total CVD and its 
subtypes for each BP category by Cox proportional hazards models in reference to the optimal 
BP category. We constructed two models to adjust for potential confounders. First, we 
adjusted for age (years), sex and cohort (model 1). Second, we further adjusted for serum total 
cholesterol (mmol/L), body mass index (BMI, kg/m2), smoking status (current, past, never)24, 
and alcohol intake (current, past, never) (model 2). 
 
To examine whether the relationship of BP category and risk of CVD death differed by age, 
we divided participants into three groups based on their age at baseline: “middle-aged” 
represented those 40 to 64 years, “elderly” represented those 65 to 74 years, and “very elderly” 
represented those 75 to 89 years. Hazard ratio (HR) and the corresponding PAF of CVD 
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deaths were estimated for each BP category in each age group. In order to assess 
heterogeneity, we assumed monotonic association of CVD risk with BP-categories, and 
created pertinent variables. In assessing heterogeneity among cohorts, we created a forest plot.  
PAF was calculated as pd×(RR-1)/RR, where pd represents the proportion of exposed deaths 
in a specific BP category, and RR is the corresponding multivariable adjusted HR in reference 
to optimal BP category25. Additionally, we calculated gender-specific mortality risks and 
PAFs for CVD, total stroke, ischemic stroke, intracerebral hemorrhage, CHD, and heart 
failure according to the BP categories. In testing statistical evidence of interaction by sex and 
BP category on the effect of CVD risk, we first visually confirmed the overall positive 
relationship between BP category and CVD risk in both sexes. Then, we created an ordinal 
variable for BP category and its interaction term with sex, and inserted them in the models.  
 
We performed the following sensitivity analyses: (a) excluding those who died from any 
cause within the first 3 years with an attempt to eliminate potential reverse causality by low 
BP 26, 27, (b) restricting the subjects to non-users of anti-hypertensive medication at baseline, 
and (c) adding diabetes mellitus (DM) status (yes, no) into the models among those 
participants with diabetes-defining variables available (n=36,393). We defined DM as either 
fasting glucose of ≥126mg/dL (7.0 mmol/L), or casual glucose of ≥200mg/dL (11.1 mmol/L), 
or hemoglobin A1c of ≥6.5%, or history of DM, or taking medication for DM. 
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All statistical analyses were performed using SAS version 9.13 (SAS Institute Inc, Cary, NC). 
All of the P values for statistical tests were two-tailed, and P values less than 0.05 were 
regarded as statistically significant. The study protocol was approved by the internal review 
board at each study center. 
 
RESULTS 
The participants’ characteristics at baseline according to BP category are shown in Table 1. 
The proportions of each BP category among all the participants (n=67,309) were 21.9% 
(optimal BP), 20.2% (normal/non-optimal BP), 21.3% (high-normal BP), 24.9% (Grade I 
hypertension), 9.0% (Grade II hypertension), and 2.7% (Grade III hypertension) at baseline. 
Compared with participants in higher BP categories, those in the optimal BP category tended 
to be younger and have a lower BMI and lower total cholesterol level at baseline. The number 
(%) of those categorized as the middle-aged, elderly, and very elderly were 49,935 (74.2%), 
13,707 (20.4%), and 3,667 (5.4%), respectively. 
 
During a mean follow up of 10.2 years, we observed 1,944 CVD deaths; 917 for total stroke, 
479 for ischemic stroke, 220 for intracerebral hemorrhage, 388 for CHD, and 343 for heart 
failure in all age-groups combined. In the Cox regression models, CVD risk increased almost 
12 
 
continuously as BP category advanced. In disease-specific analyses, risk of total stroke and 
CHD increased similarly as BP category advanced (see supplemental TableS2). PAF estimates 
indicated that elimination of normal/non-optimal BP to Grade III hypertension could have 
prevented almost half of CVD deaths. Results were similar in both sexes with no statistical 
evidence of interaction (P for interaction by sex 0.95) (see supplemental TableS3, TableS4 for 
sex-specific results).  
 
Crude death rates, adjusted hazard ratios, and PAFs according to BP category for each age 
group were shown in Table 2. The overall relationship between BP categories and CVD risk 
was positive and graded in all age groups with greater strength of association seen with 
younger group (P for heterogeneity<0.001). For both the middle-aged and elderly groups, 
CVD risk in reference to optimal BP category increased significantly from the 
normal/non-optimal BP category and continued beyond this category. For the very elderly 
group, in contrast, both optimal and normal/non-optimal BP categories appeared to be at the 
lowest CVD risk. The PAFs of CVD death beyond optimal BP category tended to be greater 
in younger groups, accounting for 60%, 49%, and 23% of all CVD deaths in the middle-aged, 
elderly, and very elderly groups, respectively. There is no statistical evidence that these trends 
differ by sex in any of the age groups (Ps for interaction by sex were 0.23, 0.11, and 0.50 for 
the middle-aged, elderly, and very elderly, respectively). (For sex-specific results by 
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age-group, see supplemental TableS5, TableS6).  
 
The forest plot by cohort indicated apparently stronger effect of BP in the YKK-workers 
cohort than other cohorts (Supplement Figure S1). However, the exclusion of this cohort did 
not change the results substantially (data not shown). We did not observe clear difference by 
methods of BP-measurement in the forest plot. 
 
In the first sensitivity analyses excluding deaths within the first 3 years, the observed 
association of BP category with CVD death became stronger in the very elderly group 
compared to that of the main result such that CVD risk significantly increased from the 
high-normal BP category and up (Table 3). Results in other age groups were similar to those 
in the main analysis. In the second sensitivity analysis, restricted to non-users of 
anti-hypertensive medication at baseline (29,097 participants, 823 CVD deaths), we observed 
similar results to the main analysis in all age groups (see supplemental TableS7). In the third 
sensitivity analysis including DM status in the model, the relationship of BP categories with 
CVD risk was attenuated in both the elderly and very elderly groups, whereas the relationship 
was slightly strengthened in the middle-aged group (see supplemental TableS8). 
 
DISCUSSION 
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This pooled analysis of 10 well-qualified, prospective cohort studies in Japan enabled us to 
investigate detailed relationship of BP categories to long-term CVD mortality risk in a broad 
age range. We found an overall positive relationship in all age groups studied. In the 
middle-aged and elderly groups, the risk was lowest at the optimal BP category. Importantly, 
the relationship appeared to increase from the high-normal BP category in a graded fashion 
even in the very elderly. The relationship became stronger in this age group when excluding 
the first 3 years of death. Another important finding of our study is that an impact of elevated 
BP, estimated by PAF, remained substantial in older groups, suggesting that maintaining 
optimal BP could have eliminated as many as one quarter of CVD deaths in the very elderly 
and half of those in the elderly.  
 
In many guidelines, categorization of BP is similar with respect to use of both SBP and DBP 
to define a category, and the same cut-off values being used irrespective of age 8-11. However, 
only a few studies have examined BP category-specific CVD risk in an elderly population. To 
our knowledge, this is the first observational study that has demonstrated a long-term CVD 
risk and its impact according to BP categories in a group of very elderly Asian men and 
women aged 75 or older. From North America/European regions, the Framingham Heart 
Study (FHS) showed that major CVD risk increased in a graded fashion with advancing BP 
categories among those aged 80 years or older 13. Most other studies from the regions 
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examined populations aged 75 years or younger 5, 14-16. The FHS observed 336 CVD events 
among 1932 elderly over a mean of 2.7 years 13. Compared with the FHS, we observed more 
than five times as many CVD events among twice as many elderly participants over a mean of 
10.2 years. Furthermore, the number of BP categories we divided into was six as compared to 
four in FHS using a modified version of the Seventh Report of the Joint National Committee 
on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) 
guidelines 9. This allows us to show finer BP-category specific CVD risks such as those for 
normal/non-optimal BP, or high-normal BP categories. Nevertheless, our results were broadly 
consistent with those in the FHS. There are a few large-scale meta-analyses, with individual 
participants data pooled, that studied association between blood pressure and CVD risk: the 
Prospective Studies Collaboration (PSC)2 and The Asia Pacific Cohort Studies Collaboration 
(APCSC)28. Having the consistent results with these studies, our study has a significant 
difference from them with respect to BP measurements. The PSC and APCSC used either 
continuous DBP or SBP alone, whereas we used BP categories that accounted for both SBP 
and DBP. Several studies from Japan have reported both BP category-specific risk and/or PAF 
on CVD events 29-33. Because of the small sample sizes, however, none of them sought 
detailed estimates for the very elderly population aged 75 or older as we did in the present 
study. A recent large prospective study from China showed both BP category-specific risk and 
PAF on CVD events 18. However, this study provided only limited information with regard to 
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BP-category specific risk and impact among the very elderly population because they grouped 
those aged 65 years or older together and used fewer BP categories that are similar to those in 
FHS. 
 
When excluding the first 3 years of death in the very elderly, we observed a stronger overall 
relationship between BP category and CVD risk with a significant increase in risk seen from 
the high-normal BP category and up. This observation may suggest the presence of reverse 
causality in which a poor health condition could have caused a lower BP 34, 35. Exclusion of 
the first few years of deaths from analysis was proposed as one way to deal with such reverse 
causality, particularly when analyzing an elderly population 26, 27, 35. Therefore, the lack of 
difference in CVD risk between the lowest two BP categories in the very elderly group may 
be attributed to reverse causality. Another possible explanation is due to an attenuated strength 
of association of BP with CVD risk in this age group compared to younger age groups 3, 28. 
 
We observed significant difference in strength of association between BP and CVD risk (i.e. 
difference in relative risk for CVD) by age-group. Such heterogeneity in the effect of blood 
pressure by age has been observed consistently in many large observational studies.18, 28, 32, 36 
However, the recent meta-analysis of clinical trials by Blood Pressure Lowering Treatment 
Trialists’ Collaboration (BPLTTC) concluded that there was no evidence for the statistical 
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heterogeneity in the effect of blood pressure lowering therapy on the CVD risk between 
younger and older subjects.37 We speculate this contrast could be due to difference in 
observational study and clinical trial, and/or due to underpower of the BPLTTC study as the 
authors of the study pointed out by themselves.37 
 
Regarding sex difference, we observed that absolute risk for CVD was generally higher in 
men than in women in all age-groups, while the relative risk of BP categories (expressed in 
hazard ratio) for CVD was similar between men and women (Supplemental tables S4 through 
S7). These findings were consistent with previous large observational studies.18, 38 
The PAF estimates calculated in our study imply greater impact of BP on CVD risk than that 
of smoking 24, 39, 40 or elevated cholesterol 41 among a Japanese population. Combined with 
the observed lower CVD risks associated with lower BP categories, the results endorse 
maintaining low BP throughout one’s life as an important strategy for CVD prevention both at 
an individual level as well as at population level. It should be emphasized, however, that our 
results do not necessarily endorse pharmaceutical treatment for hypertension because the 
study design was observational among a general population, not interventional on a group of 
patients. In fact, recent studies indicated that use of antihypertensive medication is unlikely to 
lower the risk to the same level as those who remain in low BP categories without such 
treatment 42. Furthermore, evidence on pharmaceutical treatment for hypertension in the very 
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elderly is still limited, as stated in the recent consensus document by the American College of 
Cardiology Foundation and the American Heart Association 43. 
 
Several limitations need to be considered when interpreting our results. First, we did not take 
into account for use or non-use of anti-hypertensive medication in the main analyses due to a 
substantial amount of missing information. However, the sensitivity analysis restricted to 
non-users of such medication at baseline showed similar results to the main analyses in all 
three age groups. Thus, it is less likely that this limitation would change our inference 
materially. Second, we based on a single occasion of blood pressure measurements, and did 
not account for regression dilution bias 2. Therefore, the results of the study are likely to 
underestimate of true association. Third, our estimates in the main analyses were not adjusted 
for DM. However, we found qualitatively similar results in the sensitivity analyses that 
adjusted for DM. Therefore, the influence of such a limitation on our conclusion would likely 
be small. Strength of the study includes a prospective design with long follow-up period (over 
10 years). Other strength is that the results are likely to be generalizable to wide age range of 
adult men and women given the nature of our samples obtained from across the nation. 
In summary, we observed a graded positive trend in CVD mortality risk from the high-normal 
BP category and up (SBP/DBP>130/85 mmHg) among the very elderly, and a significant 
increase in risk from normal/non-optimal BP category and up (SBP/DBP>120/80 mmHg) 
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among the middle-aged and elderly groups. The strength of association between BP categories 
and CVD risk was attenuated but remained positive and graded in the very elderly. PAFs 
revealed that keeping BP level low could avoid one quarter of CVD deaths in the very elderly 
and one half of those in the elderly. These findings suggest that maintaining low BP is an 
important strategy for primary CVD prevention in an elderly population even such as those 
aged 75 to 89 years. 
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Table 1. Baseline characteristics of participants according to blood pressure category 
                
 Blood pressure category*  
 
 Optimal    Normal/non-optimal   High-normal  
Grade I 
hypertension  
Grade II 
hypertension  
Grade III 
hypertension  
Total 
Variable (N=14764) (N=13607)  (N=14325) (N=16729) (N=6079) (N=1805) (N=67309) 
Women, % 66.1% 60.0% 56.8% 55.4% 53.6% 51.2% 58.7% 
Age, mean (SD), years 53.7 (9.7) 55.5 (10.0) 58.0 (10.0) 59.9 (10.0) 61.5 (10.0) 62.1 (10.4) 57.4 (10.3) 
Body mass index, mean 
(SD), kg/m2 
22.2 (2.8) 23.0 (2.9) 23.3 (3.0) 23.7 (3.2) 24.0 (3.4) 24.1 (3.6) 23.2 (3.1) 
Total cholesterol, mean 
(SD), mmol/L† 
5.05 (0.91) 5.11 (0.93) 5.21 (0.94) 5.23 (0.97) 5.24 (0.99) 5.27 (1.05) 5.16 (0.95) 
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Smoking        
  Never, % 69.5% 66.2% 64.4% 63.1% 61.1% 58.0% 65.1% 
  Past, % 6.7% 9.0% 10.5% 11.6% 12.4% 12.9% 9.9% 
  Current, % 23.8% 24.8% 25.2% 25.3% 26.5% 29.1% 25.1% 
Drinking        
  Never, % 61.5% 57.7% 55.6% 54.8% 53.7% 51.5% 56.8% 
  Past, % 2.7% 2.5% 2.8% 2.8% 3.0% 3.2% 2.8% 
  Current, % 35.8% 39.8% 41.6% 42.4% 43.3% 45.3% 40.4% 
* Blood pressure categories were defined as follows; "Optimal" as systolic blood pressure <120 mm Hg and diastolic blood pressure <80 mm Hg; the corresponding 
systolic and diastolic blood pressure values were 120–129 mm Hg and 80–84 mm Hg for "Normal/non-optimal," 130–139 mm Hg or 85–89 mm Hg (whichever was 
greater) for "high-normal," 140–159 mm Hg or 90–99 mm Hg for "Grade I hypertension," 160–179 mm Hg or 100–109 mm Hg for "Grade II hypertension," and ≥180 
mm Hg or ≥110 mm Hg for "Grade III hypertension." †The conversion factor for total cholesterol level from mmol/L to mg/dL is 38.67. 
27 
 
 
Table 2. Cardiovascular death according to blood pressure categories by age group  
                  
  
  Optimal Normal/non-optimal High-normal 
Grade I 
hypertension 
Grade II 
hypertension 
Grade III 
hypertension 
Total 
Very elderly (75-89y)       
 Number at risk 350  483  726  1251  616  241  3667  
 Person-year 2627  3786  5563  9655  4855  1810  28296  
 CVD death 38 45 105 206 137 60 591 
   Crude rate* 14.46  11.89  18.88  21.34  28.22  33.15  20.89  
   HR† (95% CI) 1 0.83 (0.54-1.28) 1.27 (0.87-1.84) 1.38 (0.97-1.97) 1.46 (1.01-2.12) 1.73 (1.14-2.64)  
   PAF‡ - -1.6% 3.7% 9.7% 7.3% 4.3% 23.4% 
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Elderly (65-74y)       
 Number at risk 1880  2227  3105  4290  1735  470  13707  
 Person-year 16086  19202  26249  38491  15973  4391  120392  
 CVD death 45 96 104 267 146 66 724 
   Crude rate* 2.80  5.00  3.96  6.94  9.14  15.03  6.01  
   HR† (95% CI) 1 1.76 (1.23-2.51) 1.40 (0.99-1.99) 2.20 (1.59-3.03) 2.64 (1.87-3.73) 3.96 (2.67-5.85)  
   PAF‡ - 5.7% 4.1% 20.1% 12.5% 6.8% 49.3% 
Middle-aged (40-64y)       
 Number at risk 12534  10897  10494  11188  3728  1094  49935  
 Person-year 132300  117254  109424  122301  40846  12756  534880  
 CVD death 51 87 102 194 124 71 629 
   Crude rate* 0.39  0.74  0.93  1.59  3.04  5.57  1.18  
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   HR† (95% CI) 1 1.77 (1.25-2.51) 1.94 (1.38-2.73) 2.99 (2.17-4.11) 5.23 (3.71-7.35) 8.50 (5.81-12.43)  
    PAF‡ - 6.0% 7.9% 20.5% 15.9% 10.0% 60.3% 
* Crude rate was expressed as per 1000 person-year.  †Hazard ratio was adjusted for age, sex, cohort, body mass index (kg/m2), total cholesterol (mmol/L), smoking, 
and drinking (model 2).  ‡PAF estimate was based on the hazard ratio obtained by model 2. 
HR indicates hazard ratio; 95%CI, 95% confidence intervals; PAF, population attributable fraction; CVD, cardiovascular disease. 
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Table 3. Risk of cardiovascular death in the subgroup with those died in the first 3 years excluded 
                 
   Optimal Normal/non-optimal High-normal 
Grade I 
hypertension 
Grade II 
hypertension 
Grade III 
hypertension 
Total 
Very elderly (75-89y)       
 No. at risk 296 429 648 1087 518 190 3168 
 Person-year 2518 3655 5372 9298 4620 1712 27175 
 CVD death 20 34 81 150 94 40 419 
 Crude rate* 7.94 9.3 15.08 16.13 20.35 23.37 15.42 
 HR† 1 1.17 (0.67-2.04) 1.87 (1.14-3.05) 1.91 (1.19-3.07) 1.83 (1.12-3.01) 2.14 (1.23-3.72) - 
Elderly (65-74y)       
 No. at risk 1829 2141 2980 4136 1655 437 13178 
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 Person-year 15970 18998 25923 38126 15789 4315 119120 
 CVD death 39 78 77 223 117 51 585 
 Crude rate* 2.44 4.11 2.97 5.85 7.41 11.82 4.91 
 HR† 1 1.62 (1.10-2.38) 1.19 (0.81-1.76) 2.01 (1.42-2.85) 2.26 (1.55-3.29) 3.28 (2.13-5.04) - 
Middle-aged (40-64y)       
 No. at risk 12440 10811 10400 11057 3657 1066 49431 
 Person-year 132096 117053 109187 121997 40667 12700 533700 
 CVD death 40 69 87 155 102 60 513 
 Crude rate* 0.3 0.59 0.8 1.27 2.51 4.72 0.96 
 HR† 1 1.75 (1.19-2.60) 2.08 (1.43-3.05) 2.91 (2.03-4.16) 5.21 (3.55-7.64) 8.39 (5.50-12.8) - 
*Crude rate was expressed as per 1000 person-year.   †Hazard ratio (95% confidence interval) adjusted for age (years), sex, cohort, body mass index (kg/m2), 
total cholesterol (mmol/L), smoking (current, never, past), and drinking (current, never, past) 
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CVD indicates cardiovascular disease; HR, hazard ratio. 
 
 
 
